Tag Archives: Skyhawk Therapeutics

Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More

This was a disappointing week for at least two major drug makers. French firm Genfit reported a trial failure in an intensely competitive indication, and New York-based Bristol Myers Squibb encountered a delay when the FDA declined to review its experimental multiple myeloma treatment. Genfit (NASDAQ: GNFT) was developing a treatment for nonalcoholic steatohepatitis, or […]

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis Therapeutics, a startup whose technology aims for RNA—carriers of the genetic instructions that make these proteins in the first place. The cash, an upfront payment to Waltham, MA-based Arrakis, […]

Posted in Boston, Boston blog main, Boston top stories, Europe blog main, Europe top stories, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged Arrakis Therapeutics, Biotech, cancer, clinical trials, deals, Expansion Therapeutics, Genentech, Gotham Therapeutics, Infectious Disease, investing, Life Sciences, Michael Gilman, Neuroscience, RNA, RNA drugs, Roche, Skyhawk Therapeutics | Comments Off

Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More

Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. Making changes in the midst of the study was a no-no. In recent years, regulators have showed openness to clinical trial designs intended to make drug testing more efficient. We’ll get to […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Adverum Biotechnologies, Akili Interactive, aldafermin, Alzheimer's disease, Angela Thedinga, animal health, apple, AstraZeneca, Asuragen, atopic dermatitis, Attention-deficit/hyperactivity disorder, bempedoic acid, Bicycle Therapeutics, Biogen, Biotech, cancer, cancer immunotherapy, celiac disease, Clinical Trial, coronavirus, COVID-19, Dana-Farber Cancer Institute, deals, Digital Health, dravet syndrome, Elaine Sun, Eli Lilly, eptinezumab, Erlotinib, Esperion Therapeutics, etirinotecan pegol, ezetimibe, FDA, fenfluramine, Foamix Pharmaceuticals, Fragile X Syndrome, Genentech, Gilead Sciences, Halozyme, investing, Invetx, IT, Johnson & Johnson, Karius, Laurie Stelzer, Life Sciences, Liquid Biopsy, Lundbeck, Mallinckrodt Pharmaceuticals, Marina Udier, Max Colao Aurinia Pharmaceuticals, Menlo Therapeutics, Merck, Michael Yaremchuk, Migraine, ModeRNA, MPM Capital, naloxegol, Nektar Therapeutics, NGM Biopharmaceuticals, non-alcoholic steatohepatitis, Non-Small Cell Lung Cancer, Nouscom, Opioid-Induced Constipation, opioids, Parkinson's Disease, Patricia Delaite, prurigo nodularis, pruritus, PVP Biologics, ramucirumab, RedHill BioPharma, Sangamo Therapeutics, Scipio Bioscience, Skyhawk Therapeutics, Software, Takeda Pharmaceutical, Terry Connolly, Vanda Pharmaceuticals, XenoTherapeutics, Zogenix | Comments Off

Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More

The opioid crisis reaches all corners of the nation, and newly released data this week revealed how the growth of the epidemic tracked with a massive increase in the production and distribution of these drugs. From 2006 to 2012, the number of pills distributed to pharmacies increased by more than 50 percent. In total, 76 […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged AbbVie, Acadia Pharmaceuticals, Alison Schecter, Amal Therapeutics, Astellas Pharma, Athira Pharma, Bellco Capital, Biden Cancer Initiative, Biotech, Biotech IPOs, Boehringer Ingelheim, Breakthrough Properties, cancer, cancer immunotherapy, Chemotherapy, clinical trials, complicated urinary tract infection, Corvidia Therapeutics, Cradle Genomics, deals, Diagnostics, Elon Musk, Frequency Therapeutics, Fulcrum Therapeutics, Galapagos, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Hepatitis C, Illumina, ImmuSoft, Inflammatory Diseases, investing, IPO, Joe Biden, John McHutchison, Kronos Bio, Kymera Therapeutics, Laurent Audoly, Life Sciences, Mallinckrodt Pharmaceuticals, Mark Litton, Mavuphparma, Merck, Mirum Pharmaceuticals, Navitor Pharmaceuticals, neoantigen vaccines, Neon Therapeutics, Neuralink, Neurological Diseases, niraparib (Zejula), Notable Labs, Novartis, opioid crisis, Ovarian Cancer, Pandion Therapeutics, PARP inhibitor, Pfizer, Purdue Pharma, Pyxis Oncology, RA Capital Management, Rahul Kakkar, Randy Owen, Recarbrio, RNA-targeting drugs, Robert Hayes, Selecta Biosciences, sensorineural hearing loss, Skyhawk Therapeutics, Sosei Therapeutics, SpaceX, SpecGx, Spinal Muscular Atrophy, startups, Tesaro, Tesla, Tishman Speyer, Trefoil Therapeutics, Vas Narasimhan, Zolgensma | Comments Off

Skyhawk Inks Deal With Genentech for Cancer and Neuro Drug Discovery

Skyhawk Therapeutics has added Genentech to the growing list of companies it’s working with to find new drugs. The deal with Genentech, a Roche subsidiary, calls for Cambridge, MA-based Skyhawk to use its technology to discover and develop RNA-targeting drugs for cancer and neurological diseases. Under the deal announced Tuesday, Genentech receives an exclusive license […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, San Francisco blog main, San Francisco top stories | Tagged Biogen, Biotech, cancer, Celgene, Convelo Therapeutics, deals, drug discovery, Genentech, Life Sciences, Merck, Multiple Sclerosis, Neurodegenerative Diseases, Regenerative Medicine, RNA, RNA-targeting drugs, Roche, Skyhawk Therapeutics, Spinal Muscular Atrophy, Takeda Pharmaceutical | Comments Off

Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More

The life science and healthcare worlds are vast. We often talk about impact in terms of millions of patients and billions of dollars. But these worlds can be small, too. It seems at times we’re never far removed from any one person, through their published papers, social media connections, friends, colleagues, or people they’ve mentored. […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Administration, Alzheimer's, Amgen, Bellicum Pharmaceuticals, Biogen, BioMarin Pharmaceutical, BioNtech, Biotech, Breakpoint Therapeutics, cancer, CAR-T, Celgene, Celyad, CRISPR, deafness, deals, dialysis, DNA damage, Donald Trump, Evotec, executive order, Facioscapulohumeral muscular dystrophy, Fulcrum Thearpeutics, funding, Gene editing, Gene Therapy, Greece, hemophilia, HPK1, IGM Bioscences, IPO, Kidney Care, License, Life Sciences, lower drug pricing, Max Planck Institute, medicare, Merck, Michael Becker, ModeRNA, Nimbus Therapeutics, Novartis, Obituary, PBM, Pfizer, pharmacy benefit managers, plan, price hikes, Prices, rebates, Revolution Medicines, RIP, Rivo-cel, Russia, Sangamo Therapeutics, Skyhawk Therapeutics, solid tumor, Suzanne Eaton, transparency, tv, umibecestat, uniQure, valrox, VC, Venture Capital, White House | Comments Off

The Finalists for the 2019 Xconomy Awards Are …

After a robust discussion, the editors and judges have narrowed down an impressive list of nearly 300 nominees for the 2019 Xconomy Awards in Boston to an all-star group of almost 60 finalists in 11 categories. Given the overall caliber of our nominees, we know it will be a tight race for the winners. Thankfully, we […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged Advocate, Agios Pharmaceuticals, Alexion Pharmaceuticals, Alnylam, Amylyx Pharmaceuticals, Anokion, Aoife Brennan, Beta Bionics, Big Idea, BioDirector, Biotech, Blueprint Medicines, Boston, Boston Convention and Exhibition Center, Cancer Investigator, Caroline Loew, Catalog, Cell Therapy Platform, Cellino, ceo, Cheryl Cui, commitment to diversity, Craig Crews, David Epstein, Digital Trailblazer, Doug Ingram, DynamiCare Health, eMotionRx, Entrada Therapeutics, Flagship Pioneering, FogPharma, Founder-Investor, Ginkgo BioWorks, Glympse Bio, Goldfinch Bio, Greg Verdine, healthcare, HMS Executive Education, Innovation at the Intersection, Ipsen Biopharmaceuticals, Jackie Fouse, Jason Kelly, JDRF T1D Fund, Jeff Jonas, Jordi Mata-Fink, Joseph Bolen, Joseph Kim, Joseph Vogel, Joshua Cohen, Justin Klee, Kimi Iguchi, Kyn Therapeutics, Kytopen, Leila Pirhaji, Life Science Cares, Life Sciences, LifeMine Therapeutics, Linnea Olson, Loro, Lyndra Therapeutics, Massachusetts Next Generation Initiative, Matt Kapusta, Melodie Knowlton, Mightier/Neuromotion Labs, MIT, Morphic Therapeutic, MPM Capital, Nest.Bio Labs, Newcomer, Pablo Cagnoni, Patients First, Patrick Baeuerle, pharmaceuticals, Phil Kongtcheu, Praveen Tipirneni, PureTech Health, Regina Barzilay, Relay Therapeutics, Resurrection, ReviveMed, Rodin Therapeutics, Rubius Therapeutics, Sage Therapeutics, Sarah MacDonald, Sarepta Therapeutics, Secret Weapon, Sherlock Biosciences, Skyhawk Therapeutics, Sobi (North America), Startup, Startup Artist, Stefani Spranger, Stephan Kontos, Synlogic, Talaris Therapeutics, uniQure, Vaxess Technologies, Vertex Learning Lab, Vor BioPharma, X of the Year, Xconomy Awards, xconomyawards, xconomyawardsboston, Yale University, Young Innovator | Comments Off

It’s Tough to Find Drugs to Bind to RNA: Arrakis Nabs $75M to Help

Arrakis Therapeutics has been scouting elusive pharmaceutical quarry: small molecules able to “drug” RNA, the molecular messengers that carry the genetic instructions for proteins. Most drugs in use today act on proteins. But CEO Michael Gilman says targeting the genetic blueprints could prevent RNA from translating those instructions into disease-causing proteins in the first place. […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, Raleigh-Durham blog main | Tagged Accent Therapeutics, Advent Life Sciences, Alexandria Venture Investments, Arrakis Therapeutics, Biotech, cancer, Celgene, deals, Gotham Therapeutics, GV, HBM Healthcare Investments, Henri Termeer, investing, Jennifer Petter, Life Sciences, Michael Gilman, Nextech Invest, Novartis, Obsidian Therapeutics, Omega Funds, Osage University Partners, Paul Wotton, Pfizer Ventures, Ribometrix, RNA, RNA-targeting drugs, Roche, Sigilon Therapeutics, Skyhawk Therapeutics, Small Molecule Drugs, Spinal Muscular Atrophy, University of North Carolina at Chapel Hill, VC, VenBio, Venture Capital, WuXi AppTech Venture Fund | Comments Off

Ribometrix Takes Aim at “Undruggable” RNA with $30M Series A Funding

Most drugs target proteins in the cell, but the world of RNA has remained largely untapped by companies making chemical-based, or small-molecule drugs. That’s changing though—just in the last couple of years, there’s been a mini-boom in biotechs trying to overturn the long-held dogma that messenger RNA molecules (which carry the genetic instructions for proteins […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, Raleigh-Durham, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories | Tagged Accent Therapeutics, Arrakis Therapeutics, Biotech, Expansion Therapeutics, Gotham Therapeutics, Kevin Weeks, Life Sciences, Mike Solomon, Ribometrix, RNA, Skyhawk Therapeutics, Small Molecule Drugs, startups, undruggable, University of North Carolina, University of North Carolina at Chapel Hill | Comments Off

The Winners of the 2018 Xconomy Awards Are…

This year’s nominees and finalists for the Xconomy Awards were even more impressive than last year’s (if that’s possible), making it that much tougher for our judges and the editors to pick the winners. There were multiple deserving winners in each category. But after much discussion and debate, we decided that these winners represent the […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged Abbie Celniker, Academia, Alnylam Pharmaceuticals, Angela Belcher, Biotech, Broad Institute, Business Community, David Liu, Feng Zhang, Gates Medical Research Institute, Gemini Therapeutics, Harvard Pilgrim Health Care, Human Cell Atlas, Indigo Ag, James McLaughlin, John Maraganore, Kathleen McCarthy, Leadership, Life Sciences, Liftstream, MassBio, Michael Sherman, MIT, Nancy Hopkins, Nina Dudnik, OUTBio, Partners Connected Health, Pear Therapeutics, Penny Heaton, Ramsey Johnson, Seeding Labs, Skyhawk Therapeutics, startups, Universities, VC, Venture Capital, Xconomy Awards, xconomyawardsboston | Comments Off← Older posts

Tag Archives: Skyhawk Therapeutics

Archives

Meta